Skip to main content

Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance

Vivos Therapeutics jumped more than 270% after the FDA cleared the company's devices for severe sleep apnea.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.